Immatics (IMTX) logo

Immatics (IMTX) stock

Cancer immunotherapies , market cap $906M

After-hours Fri
$5.88
+1.91%

Close $5.77 -3.03%

Why is IMTX down?

Down 34% in 3 months while the S&P 500 fell 10%.

  • It filed a prospectus for an offering of shares of $112.5M on Aug 25, 2026, its newest of 2 offering filings.

Sources: Price history, Nov 20, 2026; Prospectus supplement, Aug 25, 2026

−3Long-term trend below a falling 200-day average, down over one year, down over two years

Tell me next time IMTX moves

Free account, no card. An optional alert when IMTX moves or its score changes.Pro, $1 for a first month. An optional alert when IMTX moves or its score changes.Pro, 7 days free with a card. An optional alert when IMTX moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on IMTX →3 more reasons why IMTX is down, from its filings, with the other side, the timeline, and its peers, for Pro members.
Quality Score
-6
Poor
In its industry
#207of 273
Checks firing
3of 14
Trending down
From 52-week high
-53.5%
under its best in a year

IMTX's Quality Score rose 1 point on Fri, Nov 20, to -6. Trading was quieter than usual (2 chart checks started).

Follow IMTX's trial news. Pro members can get an alert when Immatics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when IMTX files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextEnd of 2026“…of anzu-cel (anzutresgene autoleucel, IMA203) is on track to complete the required randomizations by year-end…”Trial start · SEC filing · Nov 10

Key facts on IMTX

Key facts on IMTX
Holding it back25.3% more shares than a year ago from Massive's market data
Latest filing6-K, Nov 10 Issued a release: "Immatics Announces Third Quarter 2026 Financial Results and Business Update"

What's next

Mon Jan 11: JP Morgan 45th Annual Healthcare…Investor conference · date confirmed.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

IMTX catalysts

Coming up

After its last 4 reports it closed -0.9% on average, higher 0 of 4 times.

3 more coming up, with sizes and sources, for Pro members.

What's next for IMTX, and how long its cash lasts

Next step the company has named

End of 2026“…SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) is on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint”Trial start · SEC filing · Nov 10

What it means: when a trial begins, or reaches the stage the company named.

Lead program
IMA203 · Melanoma, Cutaneous Malignant · Phase 3
Its trial
SUPRAMEPhase 3 · Recruiting · 450 people · main data estimated Jan 2028 · NCT06743126

2 more trials, 4 more milestones and 40 filings, for Pro members.

Cash runway Dec 31, 2025 balance sheet

EUR 346M in cash

Fewer than four quarters of cash flow are on file.

What it means: a runway is counted only when each of the last four quarters used cash. It has raised money since that balance sheet, which is not counted here.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (F-3, filed Mar 27, 2025)
  • At-the-market share sales program (F-3, filed Mar 27, 2025)

For Pro members: 4 raises and their amounts, and the share count against a year ago.

Insiders

Chief Business Officer Rainer Kramer sold 22,868 shares on Nov 19. 1 more insider trade this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Jasuja Singh’s 1 filing and quote.

Get an alert when IMTX files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How IMTX ranks in Biotech

IMTX is #207 of 273 by Quality Score.

How IMTX ranks in Biotech
RankStockQuality Score
207Immatics (IMTX) logoIMTXImmatics-6

More in Biotech

When does IMTX report earnings, and what happens after?

Expected to report Thu Mar 4, before the open (in 103 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What IMTX reported on Nov 10, 2026

The quarter

A loss of €0.50 a share.

“The increase is mainly due to a higher milestone as well as higher level of activity and proportion of costs incurred relative to the overall plan in our collaboration programs within the quarter.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

IMTX's results filing gives no sales by line in a table we read. Its annual report gives the year's, in About.

The outlook

No outlook figures read from this release.

In the company's words

  • “The increase is mainly driven by higher costs associated with the SUPRAME trial in the three months ended September 30, 2026.”

From its results filing (SEC filing · Nov 10)

The numbers

Market value
$906M
today
Sales
€43.4M
down 48.8% on the year

Its figures are in EUR and its market value is in dollars, so no ratio of the two is worked out.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on IMTX: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-1.3%-1.7%-0.2%
May 12Aug 18Nov 10
ReportedGapReaction5
days
Nov 10, 2026Before open-1.7%-0.2%-4.0%
Aug 18, 2026Before open-2.0%-1.7%-6.0%
May 12, 2026Before open-0.5%-1.3%-8.0%

IMTX closed higher after 0 of its last 4 reports.

9 quarters of IMTX’s results read from its 6-K filings, the newest filed Nov 10, 2026: its sales and profit, quarter by quarter, for Pro members.

All 4 reports, and IMTX's Quality Score going into each

IMTX has 3 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on IMTX, and all 14 on every stock.Get in free →See the top 3 →Start Pro

IMTX RSI on Nov 20: 29.3, below its 50-day and 200-day averages

Not scored

RSI 29.3, MACD below signal, below both averages. Not scored.

3 more findings on IMTX, each with its source, for Pro members.

IMTX share count over time

Shares of IMTX outstanding, as filed
Shares
outstanding
As
of
134.1MDec 31, 2025
121.6MDec 31, 2024
84.7MDec 31, 2023
76.7MDec 31, 2022
Offerings, shelves, and splits of IMTX, from its filings
From its
filings
Filed
Raised $112.5M in a sale of shares, about 12% of its market valueAug 25, 2026
Raised $125M in a sale of shares, about 14% of its market valueDec 5, 2025
Registered shares for a later sale (F-3)Mar 27, 2025
Raised $150.3M in a sale of shares, about 17% of its market valueOct 11, 2024

IMTX insider trades

One insider sold $139K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest:

SellRainer Kramer$139KChief Business Officerat $6.06 on Nov 19, filed yesterday

1 buy of IMTX in the last three months is not counted as insider buys. Bought at a price outside that day's trading, so not on the market that day.

IMTX's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

About Immatics

Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

407 employeesimmatics.com

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on IMTX and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn IMTX's score around: 8 things
  • 9 more filings explained, a plain line each
  • 5 more things pulling IMTX's score down
BreakawayyesterdayRainer Kramer sold IMTX$139K at $6.06, filed Nov 20

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: IMTX's Quality Score is -6 (Poor), #207 of 273 in Biotech. Insiders sold $139K in the last 6 months (Form 4).

What does IMTX's Quality Score say?

IMTX scores -6 today, which Breakaway calls Poor. It is #207 of 273 in Biotech by Quality Score, with 3 of 14 chart checks firing. Down 34% in 3 months while the S&P 500 fell 10%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is IMTX's Quality Score?

IMTX scores -6 today, which Breakaway calls Poor (below zero). That is #207 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind IMTX's -6.

Are insiders buying IMTX?

One insider sold $139K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest is Rainer Kramer, Chief Business Officer, who sold $139K on Nov 19.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Immatics: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.